Advanced search
1 file | 236.10 KB Add to list

Amphiregulin and Epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with Cetuximab

(2009) JOURNAL OF CLINICAL ONCOLOGY. 27(30). p.5068-5074
Author
Organization
Abstract
Purpose: To study the power of the epidermal growth factor receptor (EGFR) epiregulin (EREG) and amphiregulin (AREG) ligands' expression in primary tumors to predict the outcome in patients with chemorefractory metastatic colorectal cancer (cmCRC) treated with the combination of cetuximab and irinotecan. Patients and Methods: Gene expression measurements and KRAS mutation analysis were performed on archival formalin-fixed paraffin-embedded primary tumors of 220 cmCRC patients. Response was measured using RECIST (Response Evaluation Criteria in Solid Tumors) criteria. The relation between ligand expression levels and outcome was evaluated using logistic regression for response and Cox regression for survival data. Receiver operating characteristics analysis was performed for response and survival data. CIs for the performance indices were obtained with a nonparametric bootstrap procedure. Findings were externally validated on a series of 67 samples treated in a similar setting. Results: In KRAS wild type (WT) patients, there was a significant association between log-transformed ligand expression and response for EREG (odds ratio for objective response, 1.90; 95% CI, 1.27 to 2.83; P = .0005; concordance index [c-index], 0.681) and for AREG (odds ratio for objective response, 1.862; 95% CI, 1.22 to 2.72; P = .0017; c-index, 0.673). In a Cox regression model, dichotomized ligand expression was significantly associated with progression-free survival (PFS) and overall survival (OS). EREG PFS hazard ratio (HR) was 0.41 (95% CI, 0.274 to 0.609; P < .001; time-dependent c-index [C tau index], 0.640), and AREG PFS HR was 0.43 (95% CI, 0.29 to 0.64; P < .001; C tau index, 0.627). EREG OS HR was 0.42 (95% CI, 0.28 to 0.63; P < .0001; C tau index, 0.639), and AREG OS HR was 0.40 (95% CI, 0.27 to 0.64; P < .0001; C tau index, 0.625). There was no predictive power of ligand expression in patients with KRAS mutation. Conclusion: Expression of EGFR ligands in primary tumors significantly predicts outcome in KRAS WT cmCRC treated with cetuximab and irinotecan.
Keywords
IRINOTECAN, CARCINOMA, MUTATIONS, SURVIVAL

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 236.10 KB

Citation

Please use this url to cite or link to this publication:

MLA
Jacobs, Bart et al. “Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated with Cetuximab.” JOURNAL OF CLINICAL ONCOLOGY 27.30 (2009): 5068–5074. Print.
APA
Jacobs, Bart, De Roock, W., Piessevaux, H., Van Oirbeek, R., Biesmans, B., De Schutter, J., Fieuws, S., et al. (2009). Amphiregulin and Epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with Cetuximab. JOURNAL OF CLINICAL ONCOLOGY, 27(30), 5068–5074.
Chicago author-date
Jacobs, Bart, Wendy De Roock, Hubert Piessevaux, Robin Van Oirbeek, Bart Biesmans, Jef De Schutter, Steffen Fieuws, et al. 2009. “Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated with Cetuximab.” Journal of Clinical Oncology 27 (30): 5068–5074.
Chicago author-date (all authors)
Jacobs, Bart, Wendy De Roock, Hubert Piessevaux, Robin Van Oirbeek, Bart Biesmans, Jef De Schutter, Steffen Fieuws, Jo Vandesompele, Marc Peeters, Jean-Luc Van Laethem, Yves Humblet, Frederique Penault-Llorca, Gert De Hertogh, Pierre Laurent-Puig, Eric Van Cutsem, and Sabine Tejpar. 2009. “Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated with Cetuximab.” Journal of Clinical Oncology 27 (30): 5068–5074.
Vancouver
1.
Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, et al. Amphiregulin and Epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with Cetuximab. JOURNAL OF CLINICAL ONCOLOGY. 2009;27(30):5068–74.
IEEE
[1]
B. Jacobs et al., “Amphiregulin and Epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with Cetuximab,” JOURNAL OF CLINICAL ONCOLOGY, vol. 27, no. 30, pp. 5068–5074, 2009.
@article{862710,
  abstract     = {Purpose: To study the power of the epidermal growth factor receptor (EGFR) epiregulin (EREG) and amphiregulin (AREG) ligands' expression in primary tumors to predict the outcome in patients with chemorefractory metastatic colorectal cancer (cmCRC) treated with the combination of cetuximab and irinotecan.
Patients and Methods: Gene expression measurements and KRAS mutation analysis were performed on archival formalin-fixed paraffin-embedded primary tumors of 220 cmCRC patients. Response was measured using RECIST (Response Evaluation Criteria in Solid Tumors) criteria. The relation between ligand expression levels and outcome was evaluated using logistic regression for response and Cox regression for survival data. Receiver operating characteristics analysis was performed for response and survival data. CIs for the performance indices were obtained with a nonparametric bootstrap procedure. Findings were externally validated on a series of 67 samples treated in a similar setting.
Results: In KRAS wild type (WT) patients, there was a significant association between log-transformed ligand expression and response for EREG (odds ratio for objective response, 1.90; 95% CI, 1.27 to 2.83; P = .0005; concordance index [c-index], 0.681) and for AREG (odds ratio for objective response, 1.862; 95% CI, 1.22 to 2.72; P = .0017; c-index, 0.673). In a Cox regression model, dichotomized ligand expression was significantly associated with progression-free survival (PFS) and overall survival (OS). EREG PFS hazard ratio (HR) was 0.41 (95% CI, 0.274 to 0.609; P < .001; time-dependent c-index [C tau index], 0.640), and AREG PFS HR was 0.43 (95% CI, 0.29 to 0.64; P < .001; C tau index, 0.627). EREG OS HR was 0.42 (95% CI, 0.28 to 0.63; P < .0001; C tau index, 0.639), and AREG OS HR was 0.40 (95% CI, 0.27 to 0.64; P < .0001; C tau index, 0.625). There was no predictive power of ligand expression in patients with KRAS mutation.
Conclusion: Expression of EGFR ligands in primary tumors significantly predicts outcome in KRAS WT cmCRC treated with cetuximab and irinotecan.},
  author       = {Jacobs, Bart and De Roock, Wendy and Piessevaux, Hubert and Van Oirbeek, Robin and Biesmans, Bart and De Schutter, Jef and Fieuws, Steffen and Vandesompele, Jo and Peeters, Marc and Van Laethem, Jean-Luc and Humblet, Yves and Penault-Llorca, Frederique and De Hertogh, Gert and Laurent-Puig, Pierre and Van Cutsem, Eric and Tejpar, Sabine},
  issn         = {0732-183X},
  journal      = {JOURNAL OF CLINICAL ONCOLOGY},
  keywords     = {IRINOTECAN,CARCINOMA,MUTATIONS,SURVIVAL},
  language     = {eng},
  number       = {30},
  pages        = {5068--5074},
  title        = {Amphiregulin and Epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with Cetuximab},
  url          = {http://dx.doi.org/10.1200/JCO.2008.21.3744},
  volume       = {27},
  year         = {2009},
}

Altmetric
View in Altmetric
Web of Science
Times cited: